JONATHAN J. FLEMING

jonathan-fleming-large

Jonathan J. Fleming is President and CEO of Q-State Biosciences, and early stage private funded neuroscience company in Cambridge MA. Q-State uses its proprietary technology platform to enable the discovery of new medicines for diseases such as ALS, epilepsy, Parkinson's Disease and neuropathic pain. Prior to Q State Mr. Fleming was President of NEHI (Network for Excellence in Health Innovation) a nonprofit, non-partisan health policy institute focused on enabling innovations that improve the quality and lower the costs of health care. Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, MA. Mr. Fleming has been in the investment business for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. Mr. Fleming holds a Master's degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor's degree in Political Science from the University of California, Berkeley.

JOIN US IN THE FIGHT AGAINST ALS

Whether you or a loved one is battling ALS and you want to be a part of our clinical trials, or you want to invest in the fight against this debilitating disease, we want to hear from you. Fill out the form below today and we will get back to you as quickly as possible.

  • This field is for validation purposes and should be left unchanged.